Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKinsey
Colorcon
Boehringer Ingelheim
Baxter

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIOMET ER

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Riomet Er

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00087516 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) Completed Merck Sharp & Dohme Corp. Phase 3 2004-06-01 The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00443755 Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Center for Research Resources (NCRR) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed Takeda Pharmaceuticals North America, Inc. Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed Mayo Clinic Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00682448 Metformin for the Prevention of the Metabolic Side-effects of Zyprexa Completed Eli Lilly and Company Phase 4 2007-08-01 We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
NCT00682448 Metformin for the Prevention of the Metabolic Side-effects of Zyprexa Completed Rush University Medical Center Phase 4 2007-08-01 We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Riomet Er

Condition Name

Condition Name for Riomet Er
Intervention Trials
Insulin Resistance 4
Type 2 Diabetes Mellitus 4
Type 2 Diabetes 3
Diabetes 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Riomet Er
Intervention Trials
Diabetes Mellitus 10
Diabetes Mellitus, Type 2 7
Insulin Resistance 4
Metabolic Syndrome X 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Riomet Er

Trials by Country

Trials by Country for Riomet Er
Location Trials
United States 92
South Africa 4
Mexico 4
Canada 3
Puerto Rico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Riomet Er
Location Trials
Ohio 6
Pennsylvania 5
Illinois 4
Utah 4
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Riomet Er

Clinical Trial Phase

Clinical Trial Phase for Riomet Er
Clinical Trial Phase Trials
Phase 4 8
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Riomet Er
Clinical Trial Phase Trials
Recruiting 11
Completed 9
Not yet recruiting 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Riomet Er

Sponsor Name

Sponsor Name for Riomet Er
Sponsor Trials
Merck Sharp & Dohme Corp. 4
Takeda 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Riomet Er
Sponsor Trials
Other 35
Industry 19
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Boehringer Ingelheim
McKesson
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.